Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Nivolumab in Refractory Metastatic MSS Colorectal Cancer
NCT04963283Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jun 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, nivolumab in colorectal cancer (CRC), sponsored by University of Colorado Denver. Started Jun 2021; status: active, not recruiting.
02
Drugs
cabozantinibnivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04963283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963283.